Center for Applied Proteomics and Molecular Medicine

What is Personalized Medicine?

Every individuals disease is different. Personalized medicine strives to provide the right medicine for the right patient with the lowest toxicity. Personalized cancer therapy using proteomics involves molecular profiling of the patients cancer cells to map the susceptible drug targets and thereby guide therapy. Research, like that being done by the Center for Applied Proteomics and Molecular Medicine, provides strategies for personalized treatment with the goal of providing physicians key missing molecular information about the disease in each of their patients and improving the quality of life for patients.

The Center for Applied Proteomics and Molecular Medicines mission is to: a) create new technologies and make basic science discoveries in the field of disease pathogenesis b) apply these discoveries and technologies to create and implement strategies for disease prevention, early diagnosis and individualized therapy. The primary emphasis of our disease research is cancer, but new technologies developed in the center are being applied to a number of important human diseases including cardiovascular disease, diabetes, and obesity, as well as liver, ocular, neurodegenerative and infectious diseases.

The 7th Global Reverse Phase Protein Array Workshop will be hosted in Dublin, Ireland on September 14-16, 2017. RPPA technology is a powerful multiplexed immunoassay that can quantitatively measure hundreds of proteins and post-translationally modified proteins from a limited number of cells or a fraction of a biopsy.In the last decade, RPPA has been extremely useful to:1) focus on the role of functional proteomics in the aetiology and pathogenesis of any disease.2) focus on translational-clinical biomarker research.3) design clinical trials of established and novel treatments to identify, validate and advance understanding of baseline and pharmacodynamic predictive biomarkers of drug effectiveness as well as of drug resistance mechanisms.This is only the start. Every day a growing number of basic research scientists, biomedical and pharmaceutical companies around the world find new applications for this constantly evolving technology. Regardless of whether you are a pioneer of the technology, an experienced user or a researcher interested in incorporating the technology into your portfolio, join us to discuss the next applications of this technology. These range from advances in personalized medicine to the identification of therapeutic targets and discovery and validation of biomarkers.This year in Dublin, we will continue to build on the knowledge exchanged at the previous meetings in Houston (USA) 2011, Edinburgh (UK) 2012, Kobe (Japan) 2013, Paris (France) 2014, Manassas (USA) 2015, and Tubingen (Germany) 2016.

The Side-Out Metastatic Breast cancer trial was announced at the annual meeting of the American Society of Clinical Oncology (ASCO) and is expected to expand into phase two this month.

ASCO Poster Presentation

The pilot study was the first of its kind to utilize novel protein activation mapping technology along with the genomic fingerprint of cancer as a way to find the most effective treatment. Results indicate that while prior standard chemotherapy failed the 25 women who participated in the 2.5 year pilot study, nearly half of the patients enrolled in the Side-Out trail had at least a 30 percent increase in progression-free survival.

This molecular approach creates opportunities for new therapies. For example, if a breast tumor shares the same protein pathway activation shared with lung cancer, then the drug developed to hit that target for lung cancer can be used now for breast cancer. The pilot study included only FDA-approved drugs currently on the market. Additional studies are expected to fold in new drugs as they become available with experimental drug.

Hear what patients and a treating physician has to say: Funded by Volleyball Tournaments, Breast Cancer Pilot Study Succeeds

Based on the results of this trial, CAPMM and the Side-Out Foundation are expanding this study to a new trial that is set to launch within the next month.

Read more here:
Center for Applied Proteomics and Molecular Medicine